UCSF-CAPRA Score for Prostate Cancer Risk
Formula
Pearls / Pitfalls
A prognostic score for prostate cancer, incorporating both the PSA and Gleason Score , designed to be both simple but with an accuracy comparable with the best nomograms.
Advice
For very patients, consider routine surveillance. For low to intermediate-risk patients, consider localized treatment (surgery or radiation alone, brachytherapy with or without external-beam therapy). For intermediate to high-risk patients, consider multimodal therapy (surgery with radiation, or radiation therapy with hormonal therapy). For very high-risk patients (scores ≥8 points), consider either multimodal therapy OR hormonal therapy, and clinical trial enrollment.
More Information
Score interpretation: Metastasis-free interval % likelihood (95% CI) Prostate cancer–specific survival % likelihood (95% CI) Overall survival % likelihood (95% CI) CAPRA Risk Group 5-year 10-year 5-year 10-year 5-year 10-year Low Risk Group (0-2 points) 99.3 (98.8 to 99.5) 97.5 (95.9 to 98.5) 99.7 (99.9 to 99.5) 97.1 (98.2 to 95.1) 92.5 (91.5 to 93.5) 71.4 (67.8 to 74.7) Intermediate Risk Group (3-5 points) 96.9 (96.2 to 97.5) 93.3 (91.7 to 94.6) 98.6 (99.0 to 98.1) 91.6 (93.4 to 89.5) 90.2 (89.0 to 91.3) 59.7 (56.7 to 62.7) High Risk Group (≥6 points) 90.4 (88.4 to 92.0) 83.4 (79.6 to 86.6) 93.4 (94.9 to 91.5) 79.1 (83.1 to 74.3) 78.7 (75.9 to 81.2) 42.0 (37.4 to 46.5) For more detailed risk outcomes, see Cooperberg 2009 .